Cobomarsen

DRUG3 trials

Conditions

Adult T-Cell Leukemia/Lymphoma (ATLL)Chronic Lymphocytic Leukemia (CLL)Cutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-cell Lymphoma (CTCL)Diffuse Large B-Cell Lymphoma (DLBCL), ABC SubtypeMycosis Fungoides (MF)

Phase 1

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

CompletedNCT02580552

miRagen Therapeutics, Inc.Adult T-Cell Leukemia/Lymphoma (ATLL), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-cell Lymphoma (CTCL) +2

Start: 2016-02-09End: 2020-10-06Updated: 2020-11-23

Phase 2

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

TerminatedNCT03713320

miRagen Therapeutics, Inc.Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Start: 2019-04-02End: 2020-12-01Updated: 2022-04-08

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

TerminatedNCT03837457

miRagen Therapeutics, Inc.Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Start: 2019-10-01End: 2020-07-27Updated: 2020-11-19

2020-02-27162 citations

Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.

Journal of Clinical Oncology2018-05-2022 citations

Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).

Journal of Clinical Oncology2017-05-2026 citations

Cobomarsen

Sponsors

Conditions

Phase 1

Phase 2

Related Papers